文献速递慢阻肺

基于FEV1/FVC的慢阻肺严重程度新分期STAR

FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

在COPDGene队列(N=10,132)中,用FEV1/FVC比值替代ppFEV1建立慢阻肺严重程度新分期STAR(1-4期),并在Pittsburgh队列(N=2,017)中重复验证。STAR与GOLD分期一致性高(加权Bangdiwala B=0.89和0.88),对全因死亡率等结局区分度与GOLD相似但分级更均匀,且对种族/民族等人口学特征不敏感。

要点

  • STAR用FEV1/FVC比值分级,与GOLD分期一致性高,对死亡区分度相似但更均匀。
  • STAR在症状、疾病负担和预后区分上优于基于ppFEV1的GOLD分期。
  • STAR识别出更多符合肺移植和肺减容评估条件的3/4期患者。

核心结论

  • STAR新分期对死亡率的区分与GOLD相似,但疾病严重程度分级更均匀。
  • STAR在症状、疾病负担和预后区分上优于基于ppFEV1的现有分期。
  • STAR对种族/民族和其他人口学特征较不敏感。

研究设计与样本

  • 在COPDGene队列(N=10,132)中测试STAR分期,并在Pittsburgh SCCOR与Emphysema COPD Research Registry联合队列(N=2,017)中重复验证。
  • GOLD 1-4期按ppFEV1划分:≥80%、≥50-80%、≥30-50%、<30%。
  • STAR 1-4期按FEV1/FVC划分:≥0.60至<0.70、≥0.50至<0.60、≥0.40至<0.50、<0.40。

主要发现

  • GOLD与STAR分期的加权Bangdiwala B一致性在COPDGene为0.89,在Pittsburgh队列为0.88。
  • 在COPDGene和Pittsburgh队列中,与GOLD分期相比,STAR对无气流阻塞与1期之间的全因死亡率、呼吸生活质量、呼吸困难、气道壁厚度、急性加重和肺功能下降提供显著区分。
  • 在肺气肿、小气道疾病和6分钟步行距离方面未观察到重大差异。
  • STAR分期识别出更多符合肺移植和肺减容手术评估条件的3/4期成人。

关键数值与推荐

  • GOLD 1-4期:ppFEV1≥80%、≥50-80%、≥30-50%、<30%。
  • STAR 1-4期:FEV1/FVC≥0.60至<0.70、≥0.50至<0.60、≥0.40至<0.50、<0.40。
  • GOLD与STAR一致性加权Bangdiwala B:COPDGene 0.89,Pittsburgh队列0.88。

临床怎么用

  • 可考虑用FEV1/FVC比值对慢阻肺气流阻塞严重程度进行STAR分期,以更均匀地分层预后。
  • STAR有助于识别更多适合肺移植和肺减容评估的3/4期患者。
  • STAR对种族/民族等人口学特征较不敏感,可能有助于减少分期偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The diagnosis of chronic obstructive pulmonary disease (COPD) is based on a low FEV1/FVC ratio, but the severity of COPD is classified using FEV1% predicted (ppFEV1). Objectives: To test a new severity classification scheme for COPD using FEV1/FVC ratio, a more robust measure of airflow obstruction than ppFEV1. Methods: In COPDGene (Genetic Epidemiology of COPD) (N = 10,132), the severity of airflow obstruction was categorized by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 1-4 (ppFEV1 of ⩾80%, ⩾50-80%, ⩾30-50%, and <30%). A new severity classification (STaging of Airflow obstruction by Ratio; STAR) was tested in COPDGene-FEV1/FVC ⩾0.60 to <0.70, ⩾0.50 to <0.60, ⩾0.40 to <0.50, and <0.40, respectively, for stages 1-4-and applied to the combined Pittsburgh SCCOR and Emphysema COPD Research Registry for replication (N = 2,017). Measurements and Main Results: The agreements (weighted Bangdiwala B values) between GOLD and the new FEV1/FVC ratio severity stages were 0.89 in COPDGene and 0.88 in the Pittsburgh cohort. In COPDGene and the Pittsburgh cohort, compared with GOLD staging, STAR provided significant discrimination between the absence of airflow obstruction and stage 1 for all-cause mortality, respiratory quality of life, dyspnea, airway wall thickness, exacerbations, and lung function decline. No major differences were noted for emphysema, small airway disease, and 6-minute-walk distance. The STAR classification system identified a greater number of adults with stage 3/4 disease who would be eligible for lung transplantation and lung volume reduction procedure evaluations. Conclusions: The new STAR severity classification scheme provides discrimination for mortality that is similar to the GOLD classification but with a more uniform gradation of disease severity. STAR differentiates patients' symptoms, disease burden, and prognosis better than the existing scheme based on ppFEV1, and is less sensitive to race/ethnicity and other demographic characteristics.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Bhatt SP, Nakhmani A, Fortis S, et al. FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2023. PMID: 37339502. doi:10.1164/rccm.202303-0450OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。